Search This Blog

Tuesday, February 4, 2020

HHS, Regeneron collaborating on coronavirus treatment

The Department of Health and Human Services (HHS) said Tuesday that it is collaborating with Regeneron Pharmaceuticals on a coronavirus treatment.
HHS said it would work with the company on monoclonal antibodies, which help prevent a virus from infecting human cells.
Regeneron previously worked on this type of treatment for Ebola and Middle East respiratory syndrome.
HHS is working with the company through a unit known as the Biomedical Advanced Research and Development Authority (BARDA).
“Working as public-private partners like we have with Regeneron since 2014, we can move rapidly to respond to new global health threats,” said BARDA Director Rick Bright.
The department also launched a website on Friday that allows companies to report work they are doing that could be helpful for diagnosing, preventing or treating coronavirus.
The virus has set off warnings as it has spread in China, infecting thousands of people and killing hundreds.
Dr. Anthony Fauci, the top infectious disease doctor at the National Institutes of Health, has said he hopes to start a phase one clinical trial on a vaccine for coronavirus in as soon as three months.
“We’re already working on it,” Fauci told Bloomberg late last month. “And hopefully in a period of about three months, we’ll be able to start a phase one trial in humans.”
https://thehill.com/policy/healthcare/481376-hhs-pharmaceutical-firm-collaborating-on-coronavirus-treatment

Neurocrine Biosciences EPS beats by $0.30, beats on revenue

Neurocrine Biosciences (NASDAQ:NBIX): Q4 Non-GAAP EPS of $1.05 beats by $0.30; GAAP EPS of $0.35 misses by $0.41.
Revenue of $244.1M (+85.8% Y/Y) beats by $12.56M.
https://seekingalpha.com/news/3538160-neurocrine-biosciences-eps-beats-0_30-beats-on-revenue

Qiagen EPS beats by $0.04, beats on revenue

Qiagen (NYSE:QGEN): Q4 Non-GAAP EPS of $0.48 beats by $0.04; GAAP EPS of $0.19 misses by $0.07.
Revenue of $413.47M (+2.6% Y/Y) beats by $5.05M.
https://seekingalpha.com/news/3538193-qiagen-eps-beats-0_04-beats-on-revenue

Gilead’s Biktarvy leads Q4 sales growth

Gilead Sciences (NASDAQ:GILD) Q4 results:
Revenues: $5,879M (+1.4%); product sales: $5,796M (+2.0%); HIV: $4,577M (+12.6%).
Key product sales: Biktarvy: $1,570 (+171.6%); Genvoya: $958M (-20.6%); Truvada: $768M (-6.7%); Odefsey: $435M (-2.9%); Descovy: $437M (+6.3%); Yescarta: $122M (+50.6%).
Net income: $2,696M (+999%); non-GAAP net income: $1,653M (-11.7%); EPS: $2.12 (+999%); non-GAAP EPS: $1.30 (-9.7%).
2020 guidance: Product sales: $21,800M – 22,200M; EPS: $5.15 – 5.55; non-GAAP EPS: $6.05 – 6.45.
https://seekingalpha.com/news/3538200-gileads-biktarvy-leads-q4-sales-growth

Co-Diagnostics to host webinar on development of coronavirus test

Co-Diagnostics (NASDAQ:CODX) host a webinar tomorrow, February 5, to discuss its activities developing an assay for 2019-nCoV, the coronavirus causing the current outbreak, still largely confined to China.
https://seekingalpha.com/news/3537777-co-diagnostics-to-host-webinar-on-development-of-coronavirus-test

Bristol-Myers and BioMotiv launch new drug venture

Bristol-Myers Squibb (NYSE:BMY) and drug development accelerator BioMotiv launch Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs to treat fibrotic and other inflammatory diseases. Anteros is the first such launch under the companies’ September 2019 partnership.
Under the terms of the venture, BMY will contribute intellectual property, data and reagents for a series of small molecules against an undisclosed mechanism. BioMotiv, working with Yale University, will be responsible for R&D. Once Anteros nominates a preclinical candidate, BMY will have the option to acquire Anteros from BioMotiv under pre-agreed terms.
https://seekingalpha.com/news/3537822-bristol-myers-and-biomotiv-launch-new-drug-venture

Bio-Techne fiscal Q2 top line up 6%

Bio-Techne (TECH) Q2 results: Revenues: $184.9M (+6.0%).
Net Income: $119.6M; EPS: $3.02; non-GAAP Net Income: $42.9M (+4.1%); non-GAAP EPS: $1.08 (+1.9%).
The Company formed a new joint venture focused on providing scalable manufacturing technologies and processes to develop and commercialize new cell and gene therapies.
https://seekingalpha.com/news/3537877-bio-techne-fiscal-q2-top-line-up-6